Exploring the classification of cancer cell lines from multiple omic views

Xiaoxi Yang 1, Yuqi Wen 1, Xinyu Song 2, Song He Corresp., 1, Xiaochen Bo Corresp. 1

1 Department of Biotechnology, Beijing Institute of Radiation Medicine, Beijing, China
2 Key Laboratory of Biomedical Engineering and Translational Medicine, Ministry of Industry and Information Technology, Chinese PLA General Hospital, Beijing, China

Corresponding Authors: Song He, Xiaochen Bo
Email address: hes1224@163.com, boxc@bmi.ac.cn

Background. Cancer classification is of great importance to understanding its pathogenesis, making diagnosis and developing treatment. The accumulation of extensive omics data of abundant cancer cell line provide basis for large scale classification of cancer with low cost. However, the reliability of cell lines as in vitro models of cancer has been controversial.

Methods. In this study, we explore the classification on pan-cancer cell line with single and integrated multiple omics data from the Cancer Cell Line Encyclopedia (CCLE) database. The representative omics data of cancer, mRNA data, miRNA data, copy number variation data, DNA methylation data and reverse-phase protein array data were taken into the analysis. TumorMap web tool was used to illustrate the landscape of molecular classification. The molecular classification of patient samples was compared with cancer cell lines.

Results. Eighteen molecular clusters were identified using integrated multiple omics clustering. Three pan-cancer clusters were found in integrated multiple omics clustering. By comparing with single omics clustering, we found that integrated clustering could capture both shared and complementary information from each omics data. Omics contribution analysis for clustering indicated that, although all the five omics data were of value, mRNA and proteomics data were particular important. While the classifications were generally consistent, samples from cancer patients were more diverse than cancer cell lines.

Conclusions. The clustering analysis based on integrated omics data provides a novel multi-dimensional map of cancer cell lines that can reflect the extent to pan-cancer cell lines represent primary tumors, and an approach to evaluate the importance of omic features in cancer classification.
Exploring the classification of cancer cell lines from multiple omic views

Xiaoxi Yang, Yuqi Wen, Xinyu Song, Song He and Xiaochen Bo

1 Department of Biotechnology, Beijing Institute of Radiation Medicine, Beijing, China.
2 Key Laboratory of Biomedical Engineering and Translational Medicine, Ministry of Industry and Information Technology, Chinese PLA General Hospital, Beijing, China.

Corresponding Author:
Xiaochen Bo and Song He

Taiping Road, Beijing, 100850, China.

E-mail address: boxc@bmi.ac.cn, hes1224@163.com
Abstract

Background. Cancer classification is of great importance to understanding its pathogenesis, making diagnosis and developing treatment. The accumulation of extensive omics data of abundant cancer cell line provide basis for large scale classification of cancer with low cost. However, the reliability of cell lines as in vitro models of cancer has been controversial.

Methods. In this study, we explore the classification on pan-cancer cell line with single and integrated multiple omics data from the Cancer Cell Line Encyclopedia (CCLE) database. The representative omics data of cancer, mRNA data, miRNA data, copy number variation data, DNA methylation data and reverse-phase protein array data were taken into the analysis. TumorMap web tool was used to illustrate the landscape of molecular classification. The molecular classification of patient samples was compared with cancer cell lines.

Results. Eighteen molecular clusters were identified using integrated multiple omics clustering. Three pan-cancer clusters were found in integrated multiple omics clustering. By comparing with single omics clustering, we found that integrated clustering could capture both shared and complementary information from each omics data. Omics contribution analysis for clustering indicated that, although all the five omics data were of value, mRNA and proteomics data were particular important. While the classifications were generally consistent, samples from cancer patients were more diverse than cancer cell lines.

Conclusions. The clustering analysis based on integrated omics data provides a novel multi-dimensional map of cancer cell lines that can reflect the extent to pan-cancer cell lines represent primary tumors, and an approach to evaluate the importance of omic features in cancer classification.
Introduction

Disease classification provides key foundations for identification and treatment of diseases, especially for complicated diseases such as cancer (Song et al., 2015a). Traditional classification of cancer was based on diseased organ, shared clinical symptoms and histological type (Dozmorov, 2018; Ogino et al., 2012; Song et al., 2015a). In recent years, the rapid development of high-throughput omics techniques and the accumulation of omics data enhances deeper understanding of cancer classification and characterization in oncology research (Song et al., 2015a). Molecular classification based on omics data is now becoming important evidence for individual treatment of several cancer subtypes (Koboldt et al., 2012; Tan et al., 2019). Several studies have systematically characterized molecular classification of multiple cancer types based on The Cancer Genome Atlas (TCGA) and other projects (Heim et al., 2014; International Cancer Genome et al., 2010). As early as 2014, Hoadley et al. reported an integrated analysis of 12 different cancers across six platforms, and redefined cancer types based on molecular characteristics (Hoadley et al., 2014). In 2018, the group further identified 28 distinct molecular pan-cancer subtypes arising from 33 cancers by integrating four types of omics data, providing a supplementing classification system to anatomic taxonomy (Hoadley et al., 2018).

Due to the difficulties to collect clinical samples from cancer patients, cancer cell lines had been still widely used as in vitro model for exploring cancer occurrence, development, and treatments. In some cancer types, the classification analysis of cancer cell lines has been proved to be a convenient way to characterize cancer sample subtypes. For example, five subtypes of colorectal cancer were revealed by iterative clustering of 74 different colorectal cancer cell lines, reflecting the consistency with the clinical classification of colorectal cancer patients (Schlicker et al., 2012). On the other hand, however, the reliability of cell lines as in vitro models of cancer samples has been doubted repeatedly. Previous studies have shown that in some cancer types, existing cell lines do not fully represent all tumor subtypes. For example, Domcke et al. compared the similarities and differences between the high-grade serous ovarian carcinomas cell lines and the primary tumors that they represent. They found that the most representative ovarian
carcinomas cell lines were rarely studied as in vitro models, while other ovarian cancer cell lines were commonly used (Domcke et al., 2013). In addition, there is still lack of a comprehensive and complete profiling of pan-cancer cell lines classification based on integrated multiple omics data. Recently, Li et al. used reverse phase protein arrays data to divide about 650 cell lines into 10 pan-cancer groups which contributed a molecular portrait of cancer cell lines based on proteomics (Li et al., 2017). Although great progresses have been made in the classification of pan-cancer samples based on integrated multiple omics data, there has been no research for providing an integrated molecular view of cancer cell lines based on multiple omics data and few publications have attempted to compare the classification of pan-cancer cell lines and patient samples.

In this study, we presented a systematic study on pan-cancer cell line classification based on single and integrated multiple omics data from the Cancer Cell Line Encyclopedia (CCLE) database (Ghandi et al., 2019). Our study seeks to provide a molecular classification to show a novel multi-dimensional map of pan-cancer cell lines and to compare the classification results obtained from our analysis with those of patient samples. The pan-cancer cell lines from CCLE were clustered in terms of single and multiple omics data using mRNA sequence data (mRNA), miRNA expression data (miRNA), copy number variation data (CNV), DNA methylation data (METHY) and reverse-phase protein array data (RPPA). Distinct molecular groups were identified by integrating five omics data. By characterizing each group by functional and cell-of-origin enrichment analysis, we confirmed significant molecular heterogeneity even among different cell lines of the same cancer type. Several pan-organ system clusters and a pan-squamous morphology carcinoma cluster were also found among these molecular groups. By comparing with single omics clustering, we found that integrated multiple omics clustering could significantly capture more information of omics data. Additionally, we quantified the contribution analysis of each omics data for integrated clustering. The comparison of patient samples and cell lines classification results reveals that the classification of patient samples are more diverse and abundant than cancer cell lines.
Materials & Methods

Cancer cell lines and data pre-processing

Our study involved 1,019 cell lines from 31 previously established cancer types. The mRNA, miRNA, CNV, METHY and RPPA data were downloaded from the CCLE database for all cell lines (https://portals.broadinstitute.org/ccle/data) (Ghandi et al., 2019). The number of cancer cell lines and the cancer types involved were shown in Table 1.

For mRNA sequence data, we used RSEM values in gene level shared by CCLE database. We used miRNA expression data from CCLE for miRNA analysis. For DNA methylation, the promoter CpG data was used for clustering analysis. And reverse phase protein array data was downloaded for protein analysis. In parallel, we downloaded segmented copy number profiles from CCLE database for CNV analysis. This SNP6.0 arrays data was used as the input data for Gistic2.0 software (Mermel et al., 2011). Before pre-processing the data, we mapped segmented copy number to the chromosome arm level using Gistic2.0. This copy number variation by the chromosome arm level was the input data of CNV clustering analysis. Next, the following steps were performed to improve the dataset quality for single omics clustering.

(1) For each omics dataset, cell lines with more than 20% features missing, and features with more than 20% cell lines missing were filtered out.

(2) For each omics dataset, the missing data points were filled in using average imputations.

(3) For mRNA and miRNA data, log2 (x+1) (x is the value of mRNA and miRNA) transformation were performed before feature selection.

(4) For mRNA and METHY data, only features in the top 5,000 in terms of variance were selected. For miRNA, RPPA and CNV data, all features were considered.

For integrated multiple omics clustering, 670 cell lines from 24 cancer types with complete five omics data were used after samples alignment and deletion of cancer types with few number of cell lines.

Single and multiple omics clustering of cell lines
For single omics dataset, we performed hierarchical clustering with different methods and distance measurements (Table 2). We used 30 clustering validity indices to select the optimal clustering number using the R package “NbClust” (version 3.0) (Charrad et al., 2014). The optimal parameters for function “NbClust” were set as follows: min.nc = 10, max.nc = 30, method = “average”.

The Similarity Network Fusion and Consensus clustering algorithm (SNF-CC), a method combining Similarity Network Fusion (SNF) and Consensus clustering (CC) together to take advantage of both for cancer type identification, was applied to integrate multiple omics data (Monti et al., 2003; Wang et al., 2014). The method was implemented by the R package “CancerSubtypes” (version 1.8.0) (Xu et al., 2017). The optimal parameters for function “ExecuteSNF.CC” from “CancerSubtypes” were set as follows: K = 20, alpha = 0.5, t = 20, maxK = 30, pItem = 0.8, reps = 500. The silhouette coefficient, a measurement of consistency of each object within clusters, also derived using the function “silhouette_SimilarityMatrix” from the R package “CancerSubtypes”.

The function “pamr.listgenes” from the “pamr” R package (version 1.56.1) was used to find the most suitable clustering features for the illustration of clustering by heatmap (Tibshirani et al., 2002).

Dominant cancer type and functional enrichment analysis

A hypergeometric distribution was used to calculate the P-value for cancer types in each cluster. Cancer types with a P-value < $10^{-3}$ were chosen as the dominant types of each cluster. The $-\lg(P$-value) represents the enrichment score that cancer types gathered in each cluster.

We explored the differential expressed genes (DEGs) among clusters using the R package “limma” (version 3.38.3) (Ritchie et al., 2015). Genes with adjusted P-value < 0.05 were selected, and were further screened according to $|\log2$ fold-change$| > 1$. Finally, the above DEGs were fed into enrichment analysis with GO and KEGG terms using the R package “clusterProfiler” (version 3.10.1) (Yu et al., 2012). The significantly enriched pathways were identified using false discovery rate < 0.05.
Feature contribution of integrated multiple omics clustering

We used the Normalized mutual information (NMI), which was a measure of the interdependence between two random variables, to measure the contribution of each omics type feature. The function “rankFeaturesByNMI” in the R package “SNFtool” (version 2.3.0) were used to compute NMI (Liu et al., 2018a; Wang et al., 2014). Codes are provided in Script S1.

Tumor maps of cancer cell lines

We used the TumorMap website to create pan-cancer cell lines maps from the above integrated data. TumorMap is an interactive website for assisting in exploring high-dimensional and complicated omics data (https://tumormap.ucsc.edu/) (Newton et al., 2017). In TumorMap, samples are distributed on a hexagonal grid based on their similarity and rendered using Google’s Map technology. The distances were used as input to generate a 2D layout of the samples. We used features that NMI ranks top 20% to calculate Euclidean similarity between each cell line. The Euclidean similarity is equal to 1/ (1+ Euclidean distance). All parameters in TumorMap were set default.

Results

Clustering based on single omics data

We initially clustered cell lines based on each type of omics data, which were mRNA, miRNA, CNV, METHY and RPPA data. The optimal clustering numbers were set to 10 (Fig. 1 and Fig. S1).

In the hierarchical clustering result of 901 cell lines by mRNA (Fig. 1A, Table S1 and Fig. S1A), we found that one cluster was mainly formed from a single type of cancer (C7 [SKCM]). Additionally, hematopoietic lymphatic malignancies were separated into two clusters, (C6 [ALL-DLBC-MM] and C9 [LAML-LCML]). Cancer cell lines with histological similarity or proximity tended to group together. These include C2: pan-gastrointestinal [COAD/READ-STAD], C4: nervous system tumors [GBM-LGG and some SARC whose features were the same as them] and C8: pan-gynecological [OV-UCEC and other SARC cell lines]. KEGG enrichment analysis
indicated that C1 was enriched in human cytomegalovirus infection, transcriptional misregulation in cancer, proteoglycans in cancer, TNF signaling pathway and NF-kappa B signaling pathway (Figs. S2A and S2B). Meanwhile, the cell lines in C1 were enriched in GO terms including reproductive system development and morphogenesis of embryonic epithelium (Figs. S2C-S2H).

In the clustering result of miRNA data of 879 cell lines (Fig. 1B, Table S2 and Fig. S1B), five clusters predominately contained a single cancer type (C2 [COAD/READ], C5 [STAD], C6 [HNSC], C8 [SKCM] and C10 [NB]). And tumors of the hematopoietic lymphatic system were distributed in two clusters (C4 [ALL-DLBC-LAML-LCML-MM] and C9 [ALL-DLBC-LAML]). The significant signature of these two clusters were high expression of has-miR-142-5p and has-miR-142-3p, which played an important role in lineage differentiation of hematopoietic cells (Sharma, 2017).

CNV data sorted at the chromosome arm-level for 897 cell lines were divided into 10 clusters through hierarchical clustering, four clusters mainly formed from a single cancer type (C3 [GBM], C5 [SKCM], C7 [PAAD] and C8 [SCLC]) (Fig. 1C, Table S3 and Fig. S1C). C8 was characterized by the deletion of chr3p and chr17p and the amplification of chr3q. This characterization had been reported in previous studies (Carter et al., 2017; George et al., 2015; Peifer et al., 2012). C1 and C10 were enriched for ALL, DLBC, LAML and LCML. We observed fewer alterations in C1 but more alterations in C10. For example, C10 was characterized by chr8, chr19 and chr6 copy number increase.

Among the unsupervised clustering result of 755 cell lines using METHY data (Fig. 1D, Table S4 and Fig. S1D), there was one cluster that virtually consisted of one cancer type (C7 [SKCM]). Meanwhile, hematopoietic lymphatic malignancies were still enriched in two clusters (C3 [DLBC-MM] and C6 [ALL-LAML-LCML]). Cancer cell lines originating from same organ often gathered in the same cluster, such as C2 [COAD/READ-STAD-PAAD], a group of digestive system cancers whose common features were the high expression of CNKSR1, FOLH1, ADGRG1, SMAD7, LRATD1 and MVP (Haffner et al., 2009; Ji et al., 2018;
Additionally, squamous morphology cancer cell lines aggregated by METHY patterns (C10 [ESCA-HNSC]), particularly in terms of ARHGDIB and SEPTIN9 loss (Bennett et al., 2008).

In hierarchical clustering of RPPA data from 854 cell lines (Fig. 1E, Table S5 and Fig. S1E), C4 [SKCM], C8 [LUAD] and C10 [BRCA] mostly contained one cancer type. The characteristics of C10 in this analysis had high level of ER, GATA3, AR, ERBB2, FASN, PREX1, CDH1 and CLDN7, and low level of CAV1 (Barrio-Real et al., 2016; Neve et al., 2006; Taherian-Fard et al., 2015). Hematopoietic lymphatic malignancies were enriched in one cluster (C3 [ALL-DLBC-LAML-LCML-MM]). Consistent with METHY analysis, a pan-gastrointestinal carcinoma cluster with COAD/READ-STAD was gathered in C2, which had high level of CDH1, CLDN7 and TYRO3, and a low level of CAV1 (Burgermeister et al., 2007; Di Bartolomeo et al., 2016; Qin & Qian, 2018). In addition, C7 was an enrichment cluster of squamous morphology cancer cell lines, mostly made of HNSC and ESCA and was characterized by high level of CDH1, CLDN7 and CAV1 (Ando et al., 2007; Bello et al., 2008; Shah et al., 2009).

Interestingly, some cancer types, such as SKCM, were individually classified in all five omics data, whereas some cancer types such as SCLC and BRCA were clustered individually only in one or two omics data. This result indicates that exposed information of each omics data is different at molecular level. According to investigation, SKCM is a paradigm of invasive cancer characterized by the highest mutational frequency among all cancer types and a large accumulation of changes in transcriptome (Cancer Genome Atlas N, 2015; Lawrence et al., 2013). Compared to other cancer cell lines, there are a large number of special molecular characteristics in SKCM cell lines. For example, we found that the levels of miR-188-3p and miR-514 were increased significantly, whereas in other cell lines, the levels of the two miRNA were decreased. At the CNV level, amplification of chr7 was found in most SKCM cell lines. It is generally known that several common mutations of SKCM, are on the chromosome 7 (Hayward et al., 2017). Moreover, pan-cancer clusters could be found based on mRNA, METHY
and RPPA, but were not individually clustered in miRNA and CNV. This phenomenon was consistent with feature contributions of integrated multiple omics clustering, and was related to the fact that the characteristic information from mRNA, METHY and RPPA dataset were more representative.

Integrated clustering based on multiple omics data

By using SNF-CC, we integrated all five of omics datasets (mRNA, miRNA, CNV, METHY and RPPA) across 670 cell lines and identified 18 clusters (Fig. 2A, Table S6 and Fig. S3). For these 18 clusters, 12 of them were dominated by a single cancer type (C1 [SCLC], C2[GBM], C4 [ALL], C6 [SARC], C7 [BRCA], C8 [ALL], C10 [MM], C12 [DLBC], C14 [LAML], C15 [SKCM], C16 [NB] and C17 [KIRC]) (Figs. 2A and 2B, Fig. S4). And each clusters also mixed with few amounts of other cancer types. Except SKCM, C15 also contained one glioblastoma multiforme cell line (LN229) with low level of VHL and high expression of has-miR-146a, has-miR-29b and has-miR-188-3p (Aurich et al., 2017). It is notable that although SARC is the dominant cancer types in C6, the proportion within the cluster is relatively low.

There were six clusters that dominated by two cancer types (C3 [PAAD-LUAD], C5 [HNSC-ESCA], C9 [LAML-LCML], C11 [COAD/READ-STAD], C13 [LUAD-LIHC] and C18 [OV-UCEC]) (Figs. 2A and 2B, Fig. S4). On the one hand, the proportion of two dominant cancer types were almost equal in C3, C13 and C18. And C3 was characterized by high level of CDH1. On the other hand, in C5, C9 and C11, one of the two dominant cancer type was over 50%. And C9 had high levels of VAV1 and STAT5A and low level of CTNNB1 (Bertagnolo et al., 2011; Harir et al., 2007; Ysebaert et al., 2006).

Three pan-cancer clusters influenced by organ of origin or cell morphology pattern were obtained. These clusters included pan-gastrointestinal cluster (C11 [COAD/READ-STAD]), pan-gynecological cluster (C18 [OV-UCEC]) and pan-squamous morphology carcinoma cluster (C5 [HNSC-ESCA]). For pan-gastrointestinal cluster (C11 [COAD/READ-STAD]), KEGG enrichment analysis results showed that these cell lines shared down-regulated in cytokine-cytokine receptor interaction and TNF signaling pathway (Figs. 3A, 3B and File S1). And cell
lines in C11 had high levels of protein binding involved in heterotypic cell-cell adhesion,
SNARE binding and G-protein beta-subunit binding in GO terms (Figs. 3C-3H and File S1).
Meanwhile, pan-squamous morphology carcinoma cell lines (C5 [HNSC-ESCA]) were
characterized by up-regulated of nicotine addiction and cell adhesion molecules pathway. And
these cell lines had high levels of CAV1, EGFR and ITGA2 (Ando et al., 2007; Song et al., 2015b).

We also observed two clusters with the same cancer type dispersed. For instance, cell lines
from ALL were divided into two clusters, C4 and C8, despite the common characteristics such as
Human T-cell leukemia virus 1 infection, Th17 cell differentiation, and TNF signaling pathway.
The ALL cell lines in C8 were enriched in KEGG terms including up-regulated in ECM-receptor
interaction, down-regulated in antigen processing and presentation pathway, while the ALL cell
lines in C4 had low level of cellular senescence (Figs. 3A, 3B and File S1). GO enrichment
analysis results showed that the ALL cell lines in C8 had low level of cell-cell junction and high
levels of calcium channel activity, while the ALL cell lines in C4 were down-regulated in growth
factor receptor binding and sulfur compound binding (Figs. 3C-3H and File S1). At other four
omics levels, the features of these two clusters were different as well. For example, the levels of
PTEN (a tumor suppressor gene), LCK and Syk (two immune-related genes) and has-miR-151-5p (related to tumor invasion and metastasis) was completely inconsistent.

Integrated multiple omics clustering provided a global view of cancer types because it could
capture both shared and complementary information from each omics data. Several cancer types
which mixed together in one single omics data were divided in other single omics data or
integrated omics data. For example, BRCA and SCLC were mixed together based on miRNA
data, but they were separated into two distinct molecular clusters based on integrated omics data.
Besides, in single omics clustering, three pan-organ system clusters were only found based on
mRNA data and the pan-squamous morphology carcinoma cluster was only found based on
METHY and RPPA data. But pan-gastrointestinal cluster, pan-gynecological cluster and pan-
squamous morphology carcinoma clusters were simultaneously identified by integrated multiple omics clustering.

The relative contribution of each omics data to the integrated clustering was computed based on the NMI value. On the basis of the top 20% statistical features from the five omics data, we found that RPPA and mRNA contributed 32.24% and 29.62% respectively, followed by METHY (16.24%) (Fig. 2C and Table 3). This result demonstrated that mRNA and proteomics data were particular important for cancer molecular classification. Meanwhile, more information was showed based on mRNA and RPPA data than other omics data in single omics clustering. For instance, pan-organ system clusters were identified based on mRNA and RPPA data, but not in miRNA and CNV. This results indicated that mRNA and proteomics data could be preferred if multiple omics data were not able to be measured simultaneously.

**The comparison of classification between cancer samples and cell lines**

We compared the classification results of 19 cancer types shared by cancer cell lines from CCLE and patient samples from TCGA (Hoadley et al., 2018). Clusters of patient samples and cell lines were divided into three types respectively, namely clusters dominated by single cancer type, pan-cancer clusters and clusters mixed with other cancer types (Table 4).

For hematopoietic lymphatic malignancies, the classification of cancer cell lines is more abundant than patient samples. For example, some LAML cell lines were clustered together in a group, while others were mixed with LCML cell lines into another group (LAML-LCML) in our findings. For patient samples, there is only one LAML group (Hoadley et al., 2018). The classification of DLBC cell lines was consistent with patient samples. Just like hematopoietic malignancies, the SARC patient samples were clustered individually into a group. However, for cell lines, except gathering in a single group, a few other SARC cell lines were mixed with GBM.

For most solid tumors, the classification of patient samples is generally more abundant and diverse than the corresponding cell lines. In general, patient samples with same cancer type can be divided into multiple groups, while cell lines with same cancer type are clustered in one
group. For example, the samples of breast cancer were classified into three subgroups (chr8q amp, HER2 amp and Luminal). In addition, there were a large number of BRCA samples gathered with other cancer types in a mixed cluster. Except a few of BRCA cell lines were mixed in a pan-gynecological cluster, whereas almost all BRCA cell lines were clustered in a single group. And there are similar clustering results in gastrointestinal cancer and squamous cell carcinoma. There were two pan-gastrointestinal groups and a single gastric cancer group in patient samples (Hoadley et al., 2018). While most colorectal and gastric cancer cell lines were clustered in a pan-gastrointestinal cluster without forming a STAD group in the classification result of cell lines. Most patient samples of ESCA were divided into a pan-squamous morphology carcinoma group and a pan-gastrointestinal group, while in our study, most ESCA and HNSC cell lines were clustered in a pan-squamous morphology carcinoma cluster. This indicates that not all molecular subtypes of patient samples can be represented by current panels of cancer cell lines.

On the other hand, while the number of clustering groups were same, the types of clusters were different in cell lines and patient samples of some cancer types. For example, there is a pan-kidney group in the classification of patient samples. But this cluster was not in our results because there is only one cell line associated with kidney cancer, renal clear cell carcinoma (KIRC), in the CCLE database (Hoadley et al., 2018; Ricketts et al., 2018). Although there was no pan-kidney cluster in our research, the KIRC cell lines were clustered individually in our clustering results. And the patient samples of OV and UCEC were gathered in different clusters, while cell lines of the two cancer types were clustered together in a pan-gynecological group. GBM patient samples were clustered with LGG to form a pan-cancer group, however due to lacking LGG cell lines, GBM cell lines were clustered individually. The classification of patient samples in some cancer types, such as LIHC, LUSC and THCA, the clusters they formed were dominated by single cancer type (Hoadley et al., 2018). However, the clusters formed by these three types of cancer cell lines were mixed with large number of other cancer types.
In general, due to the larger numbers of patients and the greater heterogeneity in TCGA samples, the classification results of patient samples are more diverse and abundant than cancer cell lines. It is clear that the existing cancer cell lines do not fully represent all the molecular types of corresponding patient samples. However, in some cancer types, the classification of patient samples and cell lines were consistent. This shows that cancer cell lines can represent primary samples to some extent.

**The TumorMap landscape of pan-cancer cell lines**

We used TumorMap web tool to visualize the landscape of pan-cancer cell lines. The same layout and four different color schemes (SNF-CC cluster, TCGA disease, Pan-organ system and histology) were used to reveal that most cancer cell lines gathered based on organ systems and histopathological similarity (Fig. 4). More nuance within a cancer type were apparent. The SARC was widely distributed and separated into three parts. Most of them enriched in C6 (SARC), while others were fell into C2 (GBM) characterized by amplification of chr7p and C16 (NB) characterized by chr17q amplification (Figs. 4A and 4B). Additionally, major cell lines from STAD were assembled in C11 (COAD/READ-STAD), but few gathered in C18 (OV-UCEC) and C13 (LUAD-LIHC). Pan-organ system clusters and pan-squamous morphology carcinoma cluster reported previously were shown on the map (Fig. 4C) ([Berger et al., 2018; Campbell et al., 2018; Liu et al., 2018b](#)). We found that cell lines within C11 (COAD/READ-STAD) and C5 (HNSC-ESCA) were tightly gathered, while cell lines within C18 (OV-UCEC) were relatively dispersed. The TumorMap landscape showed that cancer cell lines with similar histology characterization tended to get together, even though histological information were not used during calculating similarities (Fig. 4D). The hematopoietic lymphatic malignancies were remote from other cancer types on the map. This result underscored that the molecular characteristics of hematopoietic lymphatic malignancies were different from other cancer types (Fig. 4D). Moreover, C15 (SKCM) and C17 (KIRC) were also far away from other solid tumor groups on the map.
We downloaded the drug susceptibility data for 24 anticancer drugs across 504 cell lines in CCLE database. We used TumorMap web tool to analyze the relationship between the drug susceptibility and the pan-cancer clustering. We divided the analysis results into four types and chose the representative drugs as examples (Fig. S5).

1. These anticancer drugs have a strong effect on almost all cancer cell lines. For example, LUAD-LIHC (C13), GBM (C2), SARC (C6), DLBC (C12), SKCM (C15), OV-UCEC (C18) and HNSC-ESCA (C5) cell lines are sensitive to Paclitaxel, a broad-spectrum anticancer drug (Fig. S5A).

2. Almost all cell lines are not sensitive to these drugs, for example, L-685458, a gamma-secretase inhibitor (Fig. S5B).

3. Only one cell line or few cell lines are sensitive to these anticancer drugs. For example, as a BRAF inhibitor, PLX4720 has an obvious effect on some SKCM (C15) cell lines, but has no effect on other cell lines (Fig. S5C).

4. These anticancer drugs have a strong effect on many cancer cell lines, but have a weak effect on others. For example, RAF256 is a dual inhibitor of mutant BRAF and vascular endothelial growth factor receptor 2. This drug can inhibit proliferation of SKCM (C15), GBM (C2), LUAD-LIHC (C13), OV-UCEC (C18) and some COAD/READ-STAD (C11) cell lines (Fig. S5D).

Discussion

In this research, we provide a pan-cancer cell lines classification based on single and multiple omics data. First, unsupervised hierarchical clustering was performed using five omics data from CCLE database, involving 31 cancer types and more than 1000 cell lines, with each omics data showing different characterization. Next, we analyzed integrated multiple omics data of pan-cancer cell lines using SNF-CC method and ultimately clustered 24 cancer types into 18 groups. Moreover, we analyzed dominant cancer types and functional enrichment of each clusters. Then, the relative contribution of each omics data were calculated. We compared the classification of
cancer cell lines and patient samples. Finally, we used TumorMap web tool to illustrate the landscape of cancer cell line clusters. Our study showed that clusters were strongly influenced by organ system and cell of origin. Three pan-cancer cell line clusters: pan-gastrointestinal group, pan-gynecological group and pan-squamous morphology carcinoma group were identified by integrated multiple omics clustering simultaneously (Berger et al., 2018; Campbell et al., 2018; Liu et al., 2018b). Common functional mechanism and multiple omics characterization in the same pan-cancer clusters may contribute to potential clinical application value. The clusters obtained by integrated clustering provided reference about treating the same disease with different therapies. On one hand, one cancer type with different molecular features gathered in different clusters. Although these cell lines belong to same cancer type, the treatment therapies based on molecular characterizations may be different. On the other hand, the treatment of a cluster containing multiple cancer types may be the same. The comprehensive analysis about cancer classification could be used to elucidate potential disease mechanism and provide additional guidance for molecular treatments.

Cancer cell lines have been commonly used as in vitro models of tumors in biomedical research, however, the reliability has been doubted. The comparison of molecular classification between cancer cell lines and patient samples from TCGA provided a valuable insight into the reliability of cell lines as samples. While the overall classification of cell lines and samples were quite similar, samples from cancer patients were generally more diverse and abundant than cell lines. In some types of cancer, the number of molecular groups in patient samples were more than the corresponding cancer types of cell lines, while in others, the molecular classification of patient samples matched the corresponding molecular groups of cell lines. Our study provides researchers with a widely comparison of pan-cancer cell lines and primary samples. We also presented that mRNA and proteomics data were more strongly grouped in terms of classification by cancer type than other omics data. This is meaningful for biologists and oncologists choosing what types of omics data they need for their particular analysis.

Conclusions
In summary, we provide a novel multi-dimensional landscape of cancer cell lines, and an approach to evaluate the importance of omic features in cancer classification. This research is crucial for treating same cancer with different therapies based on molecular characteristics. The comparison of molecular classification between pan-cancer cell lines and patient samples represents a valuable resource for the reliability of available cell lines as model of tumors. With the lower cost of omics analyses and the development of high-throughput omics technologies, integrated more omics data for cancer classification could be applied in clinical diagnosis and guide personalized treatment.
References

Ando T, Ishiguro H, Kimura M, Mitsui A, Mori Y, Sugito N, Tomoda K, Mori R, Harada K, Katada T, Ogawa R, Fujii Y, and Kuwabara Y. 2007. The overexpression of caveolin-1 and caveolin-2 correlates with a poor prognosis and tumor progression in esophageal squamous cell carcinoma. Oncology Reports 18:601-609

Aurich MK, Fleming RMT, and Thiele I. 2017. A systems approach reveals distinct metabolic strategies among the NCI-60 cancer cell lines. Plos Computational Biology 13: e1005698 DOI: 10.1371/journal.pcbi.1005698.

Barrio-Real L, Wertheimer E, Garg R, Abba MC, and Kazanietz MG. 2016. Characterization of a P-Rex1 gene signature in breast cancer cells. Oncotarget 7:51335-51348 DOI: 10.18632/oncotarget.10285.

Bello IO, Vilen ST, Niinemaa A, Kantola S, Soini Y, and Salo T. 2008. Expression of claudins 1, 4, 5, and 7 and occludin, and relationship with prognosis in squamous cell carcinoma of the tongue. Human Pathology 39:1212-1220 DOI: 10.1016/j.humpath.2007.12.015.

Bennett KL, Karpenko M, Lin MT, Claus R, Arab K, Dyckhoff G, Plinkert P, Herpel E, Smiraglia D, and Plass C. 2008. Frequently methylated tumor suppressor genes in head and neck squamous cell carcinoma. Cancer Research 68:4494-4499 DOI: 10.1158/0008-5472.CAN-07-6509.

Berger AC, Korkut A, Kanchi RS, Hegde AM, Lenoir W, Liu WB, Liu YX, Fan HH, Shen H, Ravikumar V, Rao A, Schultz A, Li XB, Sumazin P, Williams C, Mestdagh P, Gunaratne PH, Yau C, Bowlby R, Robertson AG, Tiezzi DG, Wang C, Cherniack AD, Godwin AK, Kuderer NM, Rader JS, Zuna RE, Sood AK, Lazar AJ, Ojesina AI, Adebamowo C, Adebamowo SN, Baggerly KA, Chen TW, Chiu HS, Lefever S, Liu L, MacKenzie K, Orsulic S, Roszik J, Shelley CS, Song QQ, Vellano CP, Wentzensen N, Weinstein JN, Mills GB, Levine DA, Akbani R, and Network CGAR. 2018. A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Cancer Cell 33:690-705 DOI: 10.1016/j.ccell.2018.03.014.

Bertagnolo V, Nika E, Brugnoli F, Bonora M, Grassilli S, Pinton P, and Capitani S. 2011. Vav1 is a crucial molecule in monocytic/macrophagic differentiation of myeloid leukemia-derived cells. Cell and Tissue Research 345:163-175 DOI: 10.1007/s00441-011-1195-5.

Burgermeister E, Xing XB, Rocken C, Juhasz M, Chen J, Hiber M, Mair K, Shatz M, Liscovitch M, Schmid RM, and Ebert MPA. 2007. Differential expression and function of caveolin-1 in human gastric cancer progression. Cancer Research 67:8519-8526 DOI: 10.1158/0008-5472.CAN-07-1125.

Campbell JD, Yau C, Bowlby R, Liu YX, Brennan K, Fan HH, Taylor AM, Wang C, Walter V, Akbani R, Byers LA, Creighton CJ, Coarfa C, Shih J, Cherniack AD, Gevaert O, Prunello M, Shen H, Anur P, Chen JH, Cheng H, Hayes DN, Bullman S, Pedamallu CS, Ojesina AI, Sadeghi S, Mungall KL, Robertson AG, Benz C, Schultz A, Kanchi RS, Gay CM, Hegde A, Diao LX, Wang J, Ma WC, Sumazin P, Chiu HS, Chen TW, Gunaratne P, Donehower L, Rader JS, Zuna R, Al-Ahmadie H, Lazar AJ, Flores ER, Tsai KY, Zhou JH, Rustgi AK, Drill E, Shen RL, Wong CK, Stuart JM, Laird PW, Hoadley KA,
Weinstein JN, Peto M, Pickering CR, Chen Z, Waes C, and Network CGAR. 2018. Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. Cell Reports 23:194-212 DOI: 10.1016/j.celrep.2018.03.063.

Cancer Genome Atlas N. 2015. Genomic Classification of Cutaneous Melanoma. Cell 161:1681-1696 DOI: 10.1016/j.cell.2015.05.044.

Carter L, Rothwell DG, Mesquita B, Snowton C, Leong HS, Fernandez-Gutierrez F, Li Y, Burt DJ, Antonello J, Morrow CJ, Hodgkinson CL, Morris K, Priest L, Carter M, Miller C, Hughes A, Blackhall F, Dive C, and Brady G. 2017. Molecular analysis of circulating tumor cells identifies distinct copy-number profiles in patients with chemosensitive and chemorefractory small-cell lung cancer. Nature Medicine 23:114-119 DOI: 10.1038/nm.4239.

Di Bartolomeo M, Pietrantonio F, Pellegrinelli A, Martinetti A, Mariani L, Daidone MG, Bajetta E, Pelosi G, de Braud F, Floriani I, and Miceli R. 2016. Osteopontin, E-cadherin, and beta-catenin expression as prognostic biomarkers in patients with radically resected gastric cancer. Gastric Cancer 19:412-420 DOI: 10.1007/s10120-015-0495-y.

Charrad M, Ghazzali N, Boiteau V, and Niknafs A. 2014. Nbclust: An R Package for Determining the Relevant Number of Clusters in a Data Set. Journal of Statistical Software 61:1-36.

Domcke S, Sinha R, Levine DA, Sander C and Schultz N. 2013. Evaluating cell lines as tumor models by comparison of genomic profiles. Nature Communications 4:2126 DOI: 10.1038/ncomms3126.

Dozmorov MG. 2018. Disease classification: from phenotypic similarity to integrative genomics and beyond. Briefings in Bioinformatics DOI: 10.1093/bib/bby049.
Venkatesan K, Reddy A, Sonkin D, Liu M, Lehar J, Korn JM, Porter DA, Jones MD, Golji J, Caponigro G, Taylor JE, Dunning CM, Creech AL, Warren AC, McFarland JM, Zamanighomi M, Kauffmann A, Strinsky N, Imielinski M, Maruvka YE, Cherniack AD, Tsherniak A, Vazquez F, Jaffe JD, Lane AA, Weinstock DM, Johannessen CM, Morrissey MP, Stegmeier F, Schlegel R, Hahn WC, Getz G, Mills GB, Boehm JS, Golub TR, Garraway LA, and Sellers WR. 2019. Next-generation characterization of the Cancer Cell Line Encyclopedia. *Nature* 569:503-508 DOI: 10.1038/s41586-019-1186-3.

Haffner MC, Kronberger IE, Ross JS, Sheehan CE, Zitt M, Muhlmann G, Ofner D, Zelger B, Ensinger C, Yang XMJ, Geley S, Margreiter R, and Bander NH. 2009. Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. *Human Pathology* 40:1754-1761 DOI: 10.1016/j.humpath.2009.06.003.

Harir N, Pecquet C, Kerenyi M, Sonneck K, Kovacic B, Nyga R, Brevet M, Dhennin I, Gouilleux-Gruart V, Beug H, Valent P, Lassoued K, Moriggl R, and Gouilleux F. 2007. Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias. *Blood* 109:1678-1686 DOI: 10.1182/blood-2006-01-029918.

Hayward NK, Wilmott JS, Waddell N, Johansson PA, Field MA, Nones K, Patch AM, Kakavand H, Alexandrov LB, Burke H, Jakrot V, Kazakoff S, Holmes O, Leonard C, Sabarinathan R, Mularoni L, Wood S, Xu Q, Waddell N, Tembe V, Pupo GM, De Paoli-Iseppi R, Vilain RE, Shang P, Lau LMS, Dagg RA, Schramm SJ, Pritchard A, Dutton-Regester K, Newell F, Fitzgerald A, Shang CA, Grimmond SM, Pickett HA, Yang JY, Stretch JR, Behren A, Kefferd RF, Hersey P, Long GV, Cebon J, Shackleton M, Spillane AJ, Saw RPM, Lopez-Bigas N, Pearson JV, Thompson JF, Scolyer RA, and Mann GJ. 2017. Whole-genome landscapes of major melanoma subtypes. *Nature* 545:175-180 DOI: 10.1038/nature22071.

Heim D, Budczies J, Stenzinger A, Treue D, Hufnagl P, Denkert C, Dietel M, and Klauschen F. 2014. Cancer beyond organ and tissue specificity: next-generation-sequencing gene mutation data reveal complex genetic similarities across major cancers. *International Journal of Cancer* 135:2362-2369.

Hoadley KA, Yau C, Hinoue T, Wolf DM, Lazar AJ, Drill E, Shen R, Taylor AM, Cherniack AD, Thorsson V, Akbani R, Bowby R, Wong CK, Wiznerowicz M, Sanchez-Vega F, Robertson AG, Schneider BG, Lawrence MS, Noushmehr H, Malta TM, Cancer Genome Atlas N, Stuart JM, Benz CC, and Laird PW. 2018. Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. *Cell* 173:291-304 e296 DOI: 10.1016/j.cell.2018.03.022.

Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamorero D, Ng S, Leiserson MDM, Niu BF, McLellan MD, Uzunangelov V, Zhang JS, Kandoth C, Akbani R, Shen H, Omerber L, Chu A, Margolin AA, van't Veer LJ, Lopez-Bigas N, Laird PW, Raphael BJ, Ding L, Robertson AG, Byers LA, Mills GB, Weinstein JN, Van Waes C, Chen Z, Collison EA, Benz CC, Perou CM, Stuart JM, Abbott R, Abbott S, Aksoy BA, Aldape K, Ally A, Amin S, Anastassiou D, Auman JT, Baggerly KA, Balasundaram M, Balu S, Baylin SB,
Benz SC, Berman BP, Bernard B, Bhatt AS, Birol I, Black AD, Bodenheimer T, Bootwalla MS, Bowen J, Bressler R, Bristow CA, Brooks AN, Broom B, Buda E, Burton R, Butterfield YSN, Carlin D, Carter SL, Casasent TD, Chang K, Chanock S, Chin L, Cho DY, Cho J, Chuah E, Chun HJE, Cibulskis K, Ciriello G, Cleland J, Cline M, Craft B, Creighton CJ, Danilova L, Davidsen T, Davis C, Dees ND, Delehaunty K, Demchok JA, Dhalla N, DiCara D, Dinh H, Dobson JR, Dodda D, Doddapaneni H, Donehower L, Dooling DJ, Dresdner G, Drummond J, Eakin A, Edgerton M, Eldred JM, Eley G, Ellrott K, Fan C, Fei S, Felau I, Frazer S, Freeman SS, Frick J, Fronick CC, Fulton LL, Fulton R, Gabriel SB, Gao JJ, Gastier-Foster JM, Gehlenborg N, George M, Getz G, Gibbs R, Goldman M, Gonzalez-Perez A, Gross B, Guin R, Gunaratne P, Hadjipanayis A, Hamilton MP, Hamilton SR, Han L, Han Y, Harper HA, Haseley P, Haussler D, Hayes DN, Heiman DI, Helman E, Helsel C, Herbrich SM, Herman JG, Hinoue T, Hirst C, Hirst M, Holt RA, Hoyle AP, Iype L, Jacobsen A, Jeffreys SR, Jensen MA, Jones CD, Jones SJM, Ju ZL, Jung J, Kahles A, Kahn A, Kalicki-Veizer J, Kalra D, Kanchi KL, Kane DW, Kim H, Kim J, Knijnenburg T, Koboldt DC, Kovar C, Kramer R, Kreisberg R, Kucherlapati R, Ladanyi M, Lander ES, Larson DE, Lawrence MS, Lee D, Lee E, Lee S, Lee W, Lehmann KV, Leinonen K, Leraas KM, Lerner S, Levine DA, Lewis L, Ley TJ, Li HI, Li J, Li W, Liang H, Lichtenberg TM, Lin J, Lin L, Lin P, Liu WB, Liu YC, Liu YX, Lorenzi PL, Lu C, Lu YL, Luquette LJ, Ma S, Magrini VJ, Mahadeshwar HS, Mardis ER, Margolin A, Marra MA, Mayo M, McAllister C, McGUIRE SE, McMichael JF, Melott J, Meng SW, Meyerson M, Mieczkowski PA, Miller CA, Miller ML, Miller M, Moore RA, Morgan M, Morton D, Mose LE, Mungall AJ, Muzny D, Nguyen L, Noble MS, Noushmehr H, O’Laughlin M, Ojesina AI, Yang TO, Ozenberger B, Pantazi A, Parfenov M, Park PJ, Parker JS, Paull E, Pedamallu CS, Pihl T, Pohl C, Pot D, Protopopov A, Przytycka T, Radenbaugh A, Ramirez NC, Ramirez R, Ratsch G, Reid J, Ren XJ, Reva B, Reynolds SM, Rhie SK, Roach J, Rovira H, Ryan M, Saksena G, Salama S, Sander C, Santoso N, Schein JE, Schmidt H, Schultz N, Schumacher SE, Seidman J, Senbabaoglu Y, Seth S, Sharpe S, Shen RL, Sheth M, Shi Y, Shmulevich I, Silva GO, Simons JV, Sinha R, Sipahimalani P, Smith SM, Sofia HJ, Sokolov A, Soloway MG, Song XZ, Sougnez C, Spellman P, Staudt L, Stewart C, Stojanov P, Su XP, Sumer SO, Sun YC, Swatloski T, Tabak B, Tam A, Tan DH, Tang JB, Tarnuzzer R, Taylor BS, Thiessen N, Thorsson V, Triche T, Van Den Berg DJ, Vandin F, Varhol RJ, Vaske CJ, Veluvolu U, Verhaak R, Voet D, Walker J, Wallis JW, Waltman P, Wan YH, Wang M, Wang WY, Wang ZN, Waring S, Weinhold N, Weisenberger DJ, Wendl MC, Wheeler D, Wilkerson MD, Wilson RK, Wise L, Wong A, Wu CJ, Wu CC, Wu HT, Wu JY, Wylie T, Xi L, Xi RB, Xia Z, Xu AW, Yang D, Yang LM, Yang LX, Yang Y, Yao J, Yao R, Ye K, Yoshihara K, Yuan Y, Yung AK, Zack T, Zeng D, Zenklusen JC, Zhang HL, Zhang JH, Zhang NX, Zhang QY, Zhang W, Zhao W, Zheng SY, Zhu J, Zmuda E, Zou LH, and Network CGAR. 2014. Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin. Cell 158:929-944 DOI: 10.1016/j.cell.2014.06.049.
International Cancer Genome C, Hudson TJ, Anderson W, Artez A, Barker AD, Bell C, Bernabe RR, Bhan MK, Calvo F, Eerola I, Gerhard DS, Guttmacher A, Guyer M, Hemsley FM, Jennings JL, Kerr D, Klatt P, Kolar P, Kusada J, Lane DP, Laplace F, Youyong L, Nettekoven G, Ozenberger B, Peterson J, Rao TS, Remacle J, Schafer AJ, Shibata T, Stratton MR, Vockley JG, Watanabe K, Yang H, Yuen MM, Knoppers BM, Bobrow M, Cambon-Thomsen A, Dressler LG, Dyke SO, Joly Y, Kato K, Kennedy KL, Nicolas P, Parker MJ, Rial-Sebbag E, Romeo-Casabona CM, Shaw KM, Wallace S, Wiesner GL, Zeps N, Lichter P, Biankina AV, Chabannon C, Chin L, Clement B, de Alava E, Degos F, Ferguson ML, Geary P, Hayes DN, Hudson TJ, Johns AL, Kasprzyk A, Nakagawa H, Penny R, Piris MA, Sarin R, Scarpa A, Shibata T, van de Vijver M, Futreal PA, Aburatani H, Bayes M, Botwell DD, Campbell PJ, Estivill X, Gerhard DS, Grimmond SM, Gut I, Hirst M, Lopez-Otin C, Majumder P, Marra M, McPherson JD, Nakagawa H, Ning Z, Puente XS, Ruan Y, Shibata T, Stratton MR, Stunnenberg HG, Swerdlow H, Velculescu VE, Wilson RK, Xue HH, Yang L, Spellman PT, Bader GD, Boutros PC, Campbell PJ, Flicek P, Getz G, Guigo R, Guo G, Haussler D, Heath S, Hubbard TJ, Jiang T, Jones SM, Li Q, Lopez-Bigas N, Luo R, Muthuswamy L, Ouellette BF, Pearson JV, Puente XS, Quesada V, Raphael BJ, Sander C, Shibata T, Speed TP, Stein LD, Stuart JM, Teague JW, Totoki Y, Tsunoda T, Valencia A, Wheeler DA, Wu H, Zhao S, Zhou G, Stein LD, Guigo R, Hubbard TJ, Joly Y, Jones SM, Kasprzyk A, Lathrop M, Lopez-Bigas N, Ouellette BF, Spellman PT, Teague JW, Thomas G, Valencia A, Yoshida T, Kennedy KL, Axton M, Dyke SO, Futreal PA, Gerhard DS, Gunter C, Guyer M, Hudson TJ, McPherson JD, Miller LJ, Ozenberger B, Shaw KM, Kasprzyk A, Stein LD, Zhang J, Haider SA, Wang J, Yung CK, Cros A, Liang Y, Gnaneshan S, Guberian J, Hsu J, Bobrow M, Chalmers DR, Hasel KW, Joly Y, Kaan TS, Kennedy KL, Knoppers BM, Lowrance WW, Masui T, Nicolas P, Rial-Sebbag E, Rodriguez LL, Vergely C, Yoshida T, Grimmond SM, Biankin AV, Brotwell DD, Cloonan N, defazio A, Eshleman JR, Etemadmoghadam D, Gardiner BB, Kench JG, Scarpa A, Sutherland RL, Temporo MA, Waddell NJ, Wilson PJ, McPherson JD, Gallinger S, Tsao MS, Shaw PA, Petersen GM, Mukhopadhyay D, Chin L, DePinho RA, Thayer S, Muthuswamy L, Shazand K, Beck T, Sam M, Timms L, Ballin V, Lu Y, Ji J, Zhang X, Chen F, Hu X, Zhou G, Yang Q, Tian G, Zhang L, Xing X, Li X, Zhu Z, Yu Y, Yu J, Yang H, Lathrop M, Tost J, Brennan P, Holcatova I, Zardize D, Brazma A, Egevart L, Prokhortchouk E, Banks RE, Uhlen M, Cambon-Thomsen A, Viksna J, Ponten F, Skarybin K, Stratton MR, Futreal PA, Birney E, Borg A, Borresen-Dale AL, Caldas C, Fockens JA, Martin S, Reis-Filho JS, Richardson AL, Sotiriou C, Stunnenberg HG, Thoms G, van de Vijver M, van't Veer L, Calvo F, Birnbaum D, Blanche H, Boucher P, Boyault S, Chabannon C, Gut I, Masson-Jacquemier JD, Lathrop M, Paupote I, Pivot X, Vincent-Salomon A, Tabone E, Theillet C, Thomas G, Tost J, Treilleux I, Calvo F, Bioulac-Sage P, Clement B, Decaens T, Degos F, Franco D, Gut I, Gut M, Heath S, Lathrop M, Samuel D, Thomas G, Zucman-Rossi J, Lichter P, Eils R, Brors B, Korbel JO, Korshunov A, Landgraf P, Lehrach H, Pfister S, Radlwimmer B, Reifenberger G, Taylor MD, von Kalle C, Majumder PP, Sarin
R, Rao TS, Bhan MK, Scarpa A, Pederzoli P, Lawlor RA, Delledonne M, Bardelli A, Biankin AV, Grimmond SM, Gress T, Klimstra D, Zamboni G, Shibata T, Nakamura Y, Nakagawa H, Kusada J, Tsunoda T, Miyano S, Aburatani H, Kato K, Fujimoto A, Yoshida T, Campo E, Lopez-Otin C, Estivill X, Guigo R, de Sanjose S, Piris MA, Montserrat E, Gonzalez-Diaz M, Puente XS, Jares P, Valencia A, Himmelbauer H, Quesada V, Bea S, Stratton MR, Futreal PA, Campbell PJ, Vincent-Salomon A, Richardson AL, Reis-Filho JS, van de Vijver M, Thomas G, Masson-Jacquemier JD, Aparicio S, Borg A, Borresen-Dale AL, Caldas C, Foekens JA, Stunnenberg HG, van't Veer L, Easton DF, Spellman PT, Martin S, Barker AD, Chin L, Collins FS, Compton CC, Ferguson ML, Gerhard DS, Getz G, Gunter C, Guttmacher A, Guyer M, Hayes DN, Lander ES, Ozenberger B, Penny R, Peterson J, Sander C, Shaw KM, Speed TP, Spellman PT, Vockley JG, Wheeler DA, Wilson RK, Hudson TJ, Chin L, Knoppers BM, Lander ES, Lichter P, Stein LD, Stratton MR, Anderson W, Barker AD, Bell C, Bobrow M, Burke W, Collins FS, Compton CC, DePinho RA, Easton DF, Futreal PA, Gerhard DS, Green AR, Guyer M, Hamilton SR, Hubbard TJ, Kallioniemi OP, Kennedy KL, Ley TJ, Liu ET, Lu Y, Majumder P, Marra M, Ozenberger B, Peterson J, Schafer AJ, Spellman PT, Stunnenberg HG, Wainwright BJ, Wilson RK, and Yang H. 2010. International network of cancer genome projects. Nature 464:993-998 DOI: 10.1038/nature08987.

Ji B, Feng YF, Sun Y, Ji DJ, Qian WW, Zhang ZY, Wang QY, Zhang Y, Zhang C, and Sun YM. 2018. GPR56 promotes proliferation of colorectal cancer cells and enhances metastasis via epithelial-mesenchymal transition through PI3K/AKT signaling activation. Oncology Reports 40:1885-1896 DOI: 10.3892/or.2018.6582.

Kobayashi T, Masaki T, Sugiyama M, Atomi Y, Furukawa Y, and Nakamura Y. 2006. A gene encoding a family with sequence similarity 84, member A (FAM84A) enhanced migration of human colon cancer cells. International Journal of Oncology 29:341-347.

Koboldt DC, Fulton RS, McLellan MD, Schmidt H, Kalicki-Veizer J, McMichael JF, Fulton LL, Dooling DJ, Ding L, Mardis ER, Wilson RK, Ally A, Balasundaram M, Butterfield YSN, Carlsen R, Carter C, Chu A, Chuah E, Chun HJE, Coope RJN, Dhall N, Guin R, Hirst C, Hirst M, Holt RA, Lee D, Li HYI, Mayo M, Moore RA, Mungall AJ, Pleasance E, Robertson AG, Schein JE, Shaifei A, Sipahimalani P, Slobodan JR, Stoll D, Tam A, Thiessen N, Varhol RJ, Wye N, Zeng T, Zhao YJ, Birol I, Jones SJM, Marra MA, Cherniack AD, Saksena G, Onofrio RC, Pho NH, Carter SL, Schumacher SE, Tabak B, Hernandez B, Gentry J, Nguyen H, Creshaw A, Ardlie K, Beroukhim R, Winckler W, Getz G, Gabriel SB, Meyerson M, Chin L, Park PJ, Kucherlapati R, Hoadley KA, Auman JT, Fan C, Turman YJ, Shi Y, Li L, Topal MD, He XP, Chao HH, Prat A, Silva GO, Iglesia MD, Zhao W, Usary J, Berg JS, Adams M, Booker J, Wu JY, Gulabani A, Bodenheimer T, Hoyle AP, Simons JY, Soloway MG, Mose LE, Jefferys SR, Balu S, Parker JS, Hayes DN, Perou CM, Malik S, Mahurkar S, Shen H, Weisenberger DJ, Triche T, Lai PH, Bootwalla MS, Maglinte DT, Berman BP, Van den Berg DJ, Baylin SB, Laird PW, Creighton CJ, Donehower LA, Getz G, Noble M, Voet D, Saksena G,
Gehlenborg N, DiCara D, Zhang JH, Zhang HL, Wu CJ, Liu SY, Lawrence MS, Zou LH,
Sivachenko A, Lin P, Stojanov P, Jing R, Cho J, Sinha R, Park RW, Nazaire MD,
Robinson J, Thorvaldsdottir H, Mesirov J, Park PJ, Chin L, Reynolds S, Kreisberg RB,
Bernard B, Bressler R, Erkkila T, Lin J, Thorsson V, Zhang W, Shmulevich I, Ciriello G,
Weinhold N, Schultz N, Gao JJ, Cerami E, Gross B, Jacobsen A, Sinha R, Aksoy BA,
Antipin Y, Reva B, Shen RL, Taylor BS, Ladanyi M, Sander C, Anur P, Spellman PT, Lu
YL, Liu WB, Verhaak RRG, Mills GB, Akbani R, Zhang NX, Broom BM, Casasent TD,
Wakefield C, Unruh AK, Baggery K, Coombes K, Weinstein JN, Haussler D, Benz CC,
Stuart JM, Benz SC, Zhu JC, Szeto CC, Scott GK, Yau C, Paul EO, Carlin D, Wong C,
Sokolov A, Thusberg J, Mooney S, Ng S, Goldstein TC, Ellrott K, Grifford M, Wilks C,
Ma S, Craft B, Yan CH, Hu Y, Meerzaman D, Gastier-Foster JM, Bowen J, Ramirez NC,
Black AD, Pyatt RE, White P, Zmuda EJ, Frick J, Lichtenberg T, Brookens R, George
MM, Gerken MA, Harper HA, Leraas KM, Wise LJ, Tabler TR, McAllister C, Barr T,
Hart-Kothari M, Tarvin K, Saller C, Sandusky G, Mitchell C, Iacocca MV, Brown J,
Rabeno B, Czerwinski C, Petrelli N, Dolzhansky O, Abramov M, Voronina O, Potapova
O, Marks JR, Suchorska WM, Murawa D, Kycler W, Ibbis M, Korski K, Spychala A,
Murawa P, Brzezinski JJ, Perz H, Lazniak R, Teresiak M, Tatka H, Leporowska E,
Bogusz-Czerniewicz M, Malicki J, Mackiewicz A, Wiznerowicz M, Le XV, Kohl B,
Tien NV, Thorp R, Bang NV, Suessman H, Phu BD, Hajek R, Hung NP, Tran VTP,
Thang HQ, Khan KZ, Penny R, Mallery D, Curley E, Shelton C, Yena P, Ingle JN,
Couch FJ, Lingle WL, King TA, Gonzalez-Angulo AM, Mills GB, Dyer MD, Liu SY,
Meng XL, Patangan M, Waldman F, Stoppler H, Rathmell WK, Thorne L, Huang M,
Boice L, Hill A, Morrison C, Gaudioso C, Bshara W, Daily K, Eega SC, Pegram MD,
Gomez-Fernandez C, Dhir R, Bhargava R, Brufsky A, Shriver CD, Hooke JA, Campbell
JL, Mural RJ, Hu H, Somiari S, Larson C, Deyarmin B, Kvecher L, Kovatch AJ, Ellis
MJ, King TA, Hu H, Couch FJ, Mural RJ, Stricker T, White K, Olopade O, Ingle JN, Luo
CQ, Chen YQ, Marks JR, Waldman F, Wiznerowicz M, Bose R, Chang LW, Beck AH,
Gonzalez-Angulo AM, Pihl T, Jensen M, Sfeir R, Kahn A, Chu A, Kothiyl P, Wang ZN,
Snyder E, Pontius J, Ayala B, Backus M, Walton J, Baboud J, Berton D, Nicholls M,
Srinivasan D, Raman R, Girshik S, Kigonya P, Alonso S, Sanbhadti R, Barletta S, Pot D,
Sheth M, Demchok JA, Shaw KRM, Yang LM, Eley G, Ferguson ML, Tarnuzer RW,
Zhang JS, Dillon LAL, Buetow K, Fielding P, Ozenberger BA, Guyer MS, Sofia HJ,
Palchik JD, and Network CGA. 2012. Comprehensive molecular portraits of human
breast tumours. *Nature* 490:61-70 DOI: 10.1038/nature11412.

Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL,
Stewart C, Mermel CH, Roberts SA, Kiezun A, Hammerman PS, McKenna A, Drier Y,
Zou LH, Ramos AH, Pugh TJ, Stransky N, Helman E, Kim J, Sougnez C, Ambrogio L,
Nickerson E, Shefler E, Cortes ML, Auclair D, Saksena G, Voet D, Noble M, DiCara D,
Lin P, Lichtenstein L, Heiman DI, Fennell T, Imielinski M, Hernandez B, Hodis E, Baca
S, Dulak AM, Lohr J, Landau DA, Wu CJ, Melendez-Zajgla J, Hidalgo-Miranda A,
Koren A, McCarroll SA, Mora J, Crompton B, Onofrio R, Parkin M, Winckler W, Ardlie
K, Gabriel SB, Roberts CWM, Biegel JA, Stegmaier K, Bass AJ, Garraway LA, Meyerson M, Golub TR, Gordenin DA, Sunyaev S, Lander ES, and Getz G. 2013. Mutational heterogeneity in cancer and the search for new cancer-associated genes. *Nature* 499:214-218 DOI: 10.1038/nature12213.

Li J, Zhao W, Akbani R, Liu W, Ju Z, Ling S, Vellano CP, Roebuck P, Yu Q, Eterovic AK, Byers LA, Davies MA, Deng W, Gopal YN, Chen G, von Euw EM, Slamon D, Conkin D, Heymach JV, Gazdar AF, Minna JD, Myers JN, Lu Y, Mills GB, and Liang H. 2017. Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. *Cancer Cell* 31:225-239 DOI: 10.1016/j.ccell.2017.01.005.

Liu K, Guo J, Liu K, Fan P, Zeng Y, Xu C, Zhong J, Li Q, and Zhou Y. 2018a. Integrative analysis reveals distinct subtypes with therapeutic implications in KRAS-mutant lung adenocarcinoma. *EBioMedicine* 36:196-208 DOI: 10.1016/j.ebiom.2018.09.034.

Liu Y, Sethi NS, Hinoue T, Schneider BG, Cherniack AD, Sanchez-Vega F, Seoane JA, Farshidifar F, Bowby R, Islam M, Kim J, Chatila W, Akbani R, Kanchi RS, Rabkin CS, Willis JE, Wang KK, McCall SJ, Mishra L, Ojesina AI, Bullman S, Pedamallu CS, Lazar AJ, Sakai R, Thorsson V, Bass AJ, Laird PW, and Network CGAR. 2018b. Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. *Cancer Cell* 33:721-735 DOI: 10.1016/j.ccell.2018.03.010.

Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, and Getz G. 2011. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. *Genome Biology* 12:R41 DOI: 10.1186/gb-2011-12-4-r41.

Monti S, Tamayo P, Mesirov J, and Golub T. 2003. Consensus clustering: A resampling-based method for class discovery and visualization of gene expression microarray data. *Machine Learning* 52:91-118 DOI: 10.1023/A:1023949509487.

Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, and Gray JW. 2006. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. *Cancer Cell* 10:515-527 DOI: 10.1016/j.ccr.2006.10.008.

Newton Y, Novak AM, Swatloski T, McColl DC, Chopra S, Graim K, Weinstein AS, Baertsch R, Salama SR, Ellrott K, Chopra M, Goldstein TC, Haussler D, Morozova O, and Stuart JM. 2017. TumorMap: Exploring the Molecular Similarities of Cancer Samples in an Interactive Portal. *Cancer Research* 77:e111-e114 DOI: 10.1158/0008-5472.CAN-17-0580.

Ogino S, Fuchs CS, and Giovannucci E. 2012. How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. *Expert Review of Molecular Diagnostics* 12:621-628 DOI: 10.1586/Erm.12.46.
Altmuller J, Baessmann I, Becker C, de Wilde B, Vandesompele J, Bohm D, Ansen S, Gabler F, Wilkening I, Heynck S, Heuckmann JM, Lu X, Carter SL, Cibulskis K, Banerji S, Getz G, Park KS, Rauh D, Grutter C, Fischer M, Pasqualucci L, Wright G, Wainer Z, Russell P, Petersen I, Chen Y, Stoelben E, Ludwig C, Schnabl P, Hoffmann H, Muley T, Brockmann M, Engel-Riedel W, Muscarella LA, Fazio VM, Groen H, Timens W, Sietsma H, Thunnissen E, Smit E, Heideman DA, Snijders PJ, Cappuzzo F, Ligorio C, Damiani S, Field J, Solberg S, Brustugun OT, Lund-Iversen M, Sanger J, Clement JH, Soltermann A, Moch H, Weder W, Solomon B, Soria JC, Valdivie P, Besse B, Brambilla E, Brambilla C, Lantuejoul S, Lorimier P, Schneider PM, Halleg M, Pao W, Meyerson M, Sage J, Shendure J, Schneider R, Buttner R, Wolf J, Nurnberg P, Perner S, Heukamp LC, Brindle PK, Haas S, and Thomas RK. 2012. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. *Nature Genetics* 44:1104-1110 DOI: 10.1038/ng.2396.

Qin AC, and Qian WF. 2018. MicroRNA-7 inhibits colorectal cancer cell proliferation, migration and invasion via TYRO3 and phosphoinositide 3-kinase/protein B kinase/mammalian target of rapamycin pathway suppression. *International Journal of Molecular Medicine* 42:2503-2514 DOI: 10.3892/ijmm.2018.3864.

Quadri HS, Aiken TJ, Allgaeuer M, Moravec R, Attekerse S, Hussain SP, Miettinen MM, Hewitt SM, and Rudloff U. 2017. Expression of the scaffold connector enhancer of kinase suppressor of Ras 1 (CNKSR1) is correlated with clinical outcome in pancreatic cancer. *Bmc Cancer* 17: 495 DOI: 10.1186/S12885-017-3481-4.

Ricketts CJ, de Cubas AA, Fan HH, Smith CC, Lang M, Reznik E, Bowby R, Gibb EA, Akbani R, Beroukhim R, Bottaro DP, Choueiri TK, Gibbs RA, Godwin AK, Haake S, Hakimi AA, Henske EP, Hsieh JJ, Ho TH, Kanchi RS, Krishnan B, Kwikowski DJ, Lui WB, Merino MJ, Mills GB, Myers J, Nickerson ML, Reuter VE, Schmidt LS, Shelley CS, Shen H, Shuch B, Signoretta S, Srinivasan R, Tamboli P, Thomas G, Vincent BG, Vocke CD, Wheeler DA, Yang LX, Kim WT, Robertson AG, Spellman PT, Rathmell WK, Linehan WM, and Network CGAR. 2018. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. *Cell Reports* 23:313-326 DOI: 10.1016/j.celrep.2018.03.075.

Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, and Smyth GK. 2015. limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Research* 43:e47 DOI: 10.1093/nar/gkv007.

Schlicker A, Beran G, Chresta CM, McWalter G, Pritchard A, Weston S, Runswick S, Davenport S, Heathcote K, Castro DA, Orphanides G, French T, and Wessels LF. 2012. Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines. *BMC Med Genomics* 5:66 DOI: 10.1186/1755-8794-5-66.

Shah MH, Sainger RN, Telang SD, Pancholi GH, Shukla SN, and Patel PS. 2009. E-Cadherin truncation and Sialyl Lewis-X overexpression in oral squamous cell carcinoma and oral precancerous conditions. *Neoplasma* 56:40-47 DOI: 10.4149/neop_2009_01_40.

Sharma S. 2017. Immunomodulation: A definitive role of microRNA-142. *Dev Comp Immunol*
Figure 1

Cluster labels of single omics clustering.

(A) mRNA. (B) miRNA. (C) CNV. (D) METHY. (E) RPPA. A hypergeometric distribution was used to calculate the P-value for cancer types in each cluster. The rows represent clusters, and the columns represent cancer types. The values represent the -lg(P-value) of cancer types. Cancer types with -lg(P-value) > 3 in each cluster were defined as dominant cancer types. All the blank cells mean the instances of P-value = 0.
Figure 2

Classification of pan-cancer cell lines based on integrated multiple omics data.

(A) Data integrated analysis of SNF-CC. Types of cancer cell line are color-coded as shown in the right. The first track represents cell lines of TCGA disease. The second track represents the SNF-CC group. A bar graph was used to show cancer types and the proportion of cell lines in each cluster. The dominant cancer types of each cluster were marked on the top of the bar graph. (B) Clusters composition. Pie charts show the cancer type composition within clusters and the proportion of the membership. The y-coordinate of each pie center reflected the dominant cancer types proportion. The x-coordinate was determined by the number of cell lines in each cluster. (C) The contributions of feature (top 20% NMI) from each omics data.
Figure 3

KEGG and GO enrichment analyses from integrated multiple omics clustering.

(A) KEGG enrichment heatmap of down-regulated genes. (B) KEGG enrichment heatmap of up-regulated genes. (C) GO biological process enrichment heatmap of down-regulated genes. (D) GO biological process enrichment heatmap of up-regulated genes. (E) GO cellular component enrichment heatmap of down-regulated genes. (F) GO cellular component enrichment heatmap of up-regulated genes. (G) GO molecular function enrichment heatmap of down-regulated genes. (H) GO molecular function enrichment heatmap of up-regulated genes. Deeper red color signifies greater enrichment score in all panels.
Figure 4

The SNF-CC TumorMap.

The TumorMap layout was computed from cell line Euclidean similarity by NMI features, and similar cell lines were adjacent to each other. Each node represents a single cell line and is colored with attributes including (A) SNF-CC cluster, (B) TCGA disease, (C) Pan organ system and (D) Histology.
Table 1 (on next page)

The number of cancer cell lines of each type of omics data.
### Table 1:
The number of cancer cell lines of each type of omics data.

| Tumor System                          | Cancer type                                      | Abbreviation | Number of cell lines of mRNA data | Number of cell lines of miRNA data | Number of cell lines of CNV data | Number of cell lines of METHY data | Number of cell lines of RPPA data |
|---------------------------------------|--------------------------------------------------|--------------|-----------------------------------|------------------------------------|----------------------------------|-----------------------------------|----------------------------------|
| Hematopoietic lymphatic malignancies  | acute lymphoblastic leukemia                     | ALL          | 31                                | 31                                 | 32                               | 30                                | 29                               |
|                                       | chronic lymphoblastic leukemia                    | CLL          | 4                                 | 4                                  | 4                                | 2                                 | 4                                |
|                                       | lymphoid neoplasm diffuse large B-cell lymphoma   | DLBC         | 39                                | 39                                 | 40                               | 37                                | 37                               |
| Urologic system malignancies          | acute myeloid leukemia                            | LAML         | 35                                | 31                                 | 36                               | 28                                | 31                               |
|                                       | chronic myeloid leukemia                          | LCML         | 14                                | 14                                 | 15                               | 11                                | 13                               |
|                                       | multiple myeloma                                  | MM           | 28                                | 28                                 | 30                               | 19                                | 27                               |
|                                       | bladder urothelial carcinoma                     | BLCA         | 25                                | 25                                 | 23                               | 19                                | 24                               |
|                                       | kidney renal clear cell carcinoma                 | KIRC         | 33                                | 23                                 | 36                               | 21                                | 21                               |
|                                       | prostate adenocarcinoma                           | PARD         | 8                                 | 7                                  | 8                                | 6                                 | 7                                |
|                                       | breast invasive carcinoma                        | BRCA         | 51                                | 50                                 | 53                               | 46                                | 47                               |
| Gynecologic cancers                  | cervical squamous cell carcinoma and endocervical adenocarcinoma | CESC         | 2                                 | 0                                  | 0                                | 0                                 | 0                                |
|                                       | ovarian carcinoma                                 | OV           | 47                                | 49                                 | 49                               | 43                                | 47                               |
|                                       | uterine corpus endometrial carcinoma             | UCEC         | 28                                | 28                                 | 28                               | 22                                | 28                               |
|                                       | cholangiocarcinoma                                | CHOL         | 8                                 | 8                                  | 0                                | 7                                 | 8                                |
|                                       | colon adenocarcinoma/rectum adenocarcinoma        | COAD/READ    | 59                                | 58                                 | 57                               | 52                                | 57                               |
| Digestive system tumors              | esophageal carcinoma                              | ESCA         | 27                                | 25                                 | 27                               | 17                                | 26                               |
|                                       | liver hepatocellular carcinoma                   | LIHC         | 25                                | 25                                 | 26                               | 19                                | 23                               |
|                                       | pancreatic adenocarcinoma                         | PAAD         | 41                                | 40                                 | 43                               | 35                                | 40                               |
| Nervous system tumors | STAD | GBM | LGG | MB | NB | LUAD |
|-----------------------|------|-----|-----|----|----|------|
| stomach adenocarcinoma| 37   | 37  | 38  | 32 | 37 |
| glioblastoma multiforme| 37   | 37  | 38  | 32 | 37 |
| brain lower grade glioma | 33   | 33  | 34  | 30 | 34 |
| medulloblastoma | 10   | 9   | 13  | 6  | 9  |
| neuroblastoma | 16   | 16  | 17  | 14 | 16 |
| lung adenocarcinoma | 76   | 73  | 70  | 62 | 74 |
| Thoracic tumors | LUSC | MESO | SCLC | HNSC | SARC | SKCM | THCA |
| lung squamous cell carcinoma | 26   | 25  | 23  | 15 | 21 |
| mesothelioma | 9    | 9   | 9   | 7  | 8  |
| small cell lung cancer | 50   | 50  | 53  | 47 | 45 |
| head and neck squamous cell carcinoma | 33   | 33  | 32  | 31 | 32 |
| Others | 37   | 38  | 31  | 31 | 37 |
| sarcoma | 54   | 55  | 54  | 51 | 55 |
| skin cutaneous melanoma | 11   | 12  | 12  | 11 | 12 |
Table 2 (on next page)

Methods and measurements for hierarchical clustering.
Table 2: Methods and measurements for hierarchical clustering.

| Omics data | Method | Distance Measurement |
|------------|--------|----------------------|
| mRNA       | ward.D | 1-Pearson’s correlation coefficient |
| miRNA      | ward.D2| 1-Pearson’s correlation coefficient |
| CNV        | ward.D2| Manhattan Distance   |
| METHY      | ward.D | 1-Pearson’s correlation coefficient |
| RPPA       | ward.D2| 1-Pearson’s correlation coefficient |
Table 3 (on next page)

The percentages of the top 20% NMI features from each omics data.
|                  | mRNA | miRNA | CNV | METHY | RPPA |
|------------------|------|-------|-----|-------|------|
| The top 20% NMI features | 5626 | 67    | 1   | 7691  | 69   |
| All features     | 18,996 | 654  | 40  | 47,362 | 214  |
| Percentage       | 29.62% | 10.24% | 2.50% | 16.24% | 32.24% |
Table 4 (on next page)

The comparison of classification between cancer samples and cell lines.
Table 4: The comparison of classification between cancer samples and cell lines.

| Cancer types | Classification of cancer samples in TCGA | Classification of cell lines in CCLE |
|--------------|------------------------------------------|-------------------------------------|
|              | Number of clusters dominated by single cancer type | Number of pan-cancer clusters | Number of clusters mixed with other cancer types | Number of clusters dominated by single cancer type | Number of pan-cancer clusters | Number of clusters mixed with other cancer types |
| DLBC         | 1                                        | 0                                  | 0                                       | 1                                         | 0                                         | 0                                         |
| LAML         | 1                                        | 0                                  | 0                                       | 1                                         | 0                                         | 1                                         |
| BLCA         | 0                                        | 0                                  | 1                                       | 0                                         | 0                                         | 1                                         |
| KIRC         | 0                                        | 1                                  | 0                                       | 1                                         | 0                                         | 0                                         |
| BRCA         | 3                                        | 0                                  | 1                                       | 1                                         | 0                                         | 0                                         |
| OV           | 1                                        | 0                                  | 0                                       | 0                                         | 1                                         | 0                                         |
| UCEC         | 1                                        | 0                                  | 0                                       | 0                                         | 1                                         | 0                                         |
| COAD/READ    | 0                                        | 2                                  | 0                                       | 0                                         | 1                                         | 0                                         |
| ESCA         | 0                                        | 2                                  | 0                                       | 0                                         | 1                                         | 0                                         |
| LIHC         | 1                                        | 0                                  | 0                                       | 0                                         | 0                                         | 1                                         |
| PAAD         | 0                                        | 0                                  | 1                                       | 0                                         | 0                                         | 1                                         |
| STAD         | 1                                        | 1                                  | 1                                       | 0                                         | 1                                         | 0                                         |
| GBM          | 0                                        | 1                                  | 0                                       | 1                                         | 0                                         | 0                                         |
| LUAD         | 1                                        | 0                                  | 0                                       | 0                                         | 0                                         | 2                                         |
| LUSC         | 0                                        | 1                                  | 0                                       | 0                                         | 0                                         | 1                                         |
| HNSC         | 0                                        | 2                                  | 0                                       | 0                                         | 1                                         | 0                                         |
| SARC         | 0                                        | 0                                  | 1                                       | 1                                         | 0                                         | 1                                         |
| SKCM         | 0                                        | 0                                  | 1                                       | 1                                         | 0                                         | 0                                         |
| THCA         | 1                                        | 0                                  | 0                                       | 0                                         | 0                                         | 1                                         |